Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference
Puma Biotechnology, Inc. (PBYI) CEO Alan H. Auerbach to attend TD Cowen's 44th Annual Health Care Conference in Boston. Auerbach will participate in a Breast & Lung Cancer Corporate Panel Discussion on March 6, 2024, at 9:10 a.m. ET.
02/22/2024 - 04:10 PM
LOS ANGELES --(BUSINESS WIRE)--
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will attend TD Cowen’s 44th Annual Health Care Conference, which will be held March 4 – 6, 2024, at the Boston Marriott Copley Place in Boston . Mr. Auerbach will participate in a Breast & Lung Cancer Corporate Panel Discussion on March 6 at 9:10 a.m. ET.
A live webcast of the Breast & Lung Cancer Corporate Panel Discussion will be available at https://wsw.com/webcast/cowen154/panel9/2257542 , and a replay will be available on Puma’s website for 30 days following the presentation at https://www.pumabiotechnology.com/ir_events.html .
About Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licensed the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX® is a registered trademark of Puma Biotechnology, Inc.
In September 2022, Puma entered into an exclusive license agreement for the development and commercialization of the anti-cancer drug alisertib, a selective, small molecule, orally administered inhibitor of aurora kinase A. Initially, Puma intends to focus the development of alisertib on the treatment of small cell lung cancer and breast cancer. In February 2024, Puma initiated ALISCA-Lung 1, a Phase II clinical trial of alisertib monotherapy for the treatment of patients with extensive stage small cell lung cancer.
Further information about Puma Biotechnology may be found at https://www.pumabiotechnology.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20240222267179/en/
Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
David Schull or Olipriya Das, Russo Partners, +1 212 845 4200
david.schull@russopartnersllc.com
olipriya.das@russopartnersllc.com
Source: Puma Biotechnology, Inc.
When will Alan H. Auerbach attend TD Cowen's 44th Annual Health Care Conference?
Alan H. Auerbach will attend TD Cowen's 44th Annual Health Care Conference on March 4 - 6, 2024, in Boston.
What will Alan H. Auerbach participate in at the conference?
Alan H. Auerbach will participate in a Breast & Lung Cancer Corporate Panel Discussion on March 6, 2024, at 9:10 a.m. ET.
Where can a live webcast of the panel discussion be viewed?
A live webcast of the panel discussion will be available at https://wsw.com/webcast/cowen154/panel9/2257542.
Where can a replay of the panel discussion be accessed?
A replay of the panel discussion will be available on Puma's website for 30 days following the presentation at https://www.pumabiotechnology.com/ir_events.html.
